FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111257261> ?p ?o ?g. }

• W3111257261 endingPage "266" @default.
• W3111257261 startingPage "257" @default.
• W3111257261 abstract "ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) and an EGFR-activating mutation, reported significant improvement in overall survival (OS) with dacomitinib. This paper reports an updated OS analysis of ARCHER 1050 after an extended follow-up. In this multinational, multicenter trial, adults (aged ≥ 18 years or ≥ 20 years in Japan and Korea) with newly diagnosed NSCLC and EGFR mutation (exon 19 deletion or exon 21 L858R substitution), and no history of central nervous system metastases, were randomized 1:1 to receive dacomitinib 45 mg/day (n = 227) or gefitinib 250 mg/day (n = 225). Randomization was stratified by race and EGFR mutation type. An ad hoc updated analysis of OS was conducted at the protocol-defined cut-off of 48 months from first dosing of the last enrolled patient (13 May 2019). After a median follow-up of 47.9 months, 133 (58.6%) patients had died in the dacomitinib arm and 152 (67.6%) in the gefitinib arm. The hazard ratio (HR) for OS was 0.748 (95% CI 0.591–0.947; two-sided P = 0.0155); median OS was 34.1 months with dacomitinib versus 27.0 months with gefitinib. The HR for OS in patients with dose reduction(s) in the dacomitinib arm (n = 154) compared with all patients in the gefitinib arm was 0.554 (95% CI 0.420–0.730); median OS was 42.5 months for patients with dose reduction(s) in the dacomitinib arm. The most common adverse events were diarrhea (87.7%), paronychia (61.7%), dermatitis acneiform (49.3%), and stomatitis (43.6%) with dacomitinib, and diarrhea (55.8%) and alanine aminotransferase increased (40.2%) with gefitinib. The OS benefit from first-line treatment with dacomitinib versus gefitinib was maintained after extended follow-up in patients with advanced NSCLC with EGFR-activating mutations. NCT01774721 (registered 24 January 2013)." @default.
• W3111257261 created "2020-12-21" @default.
• W3111257261 creator A5003464447 @default.
• W3111257261 creator A5005962138 @default.
• W3111257261 creator A5011935052 @default.
• W3111257261 creator A5016050402 @default.
• W3111257261 creator A5024261346 @default.
• W3111257261 creator A5026909873 @default.
• W3111257261 creator A5028631107 @default.
• W3111257261 creator A5035532245 @default.
• W3111257261 creator A5038776794 @default.
• W3111257261 creator A5043607755 @default.
• W3111257261 creator A5044887899 @default.
• W3111257261 creator A5052159787 @default.
• W3111257261 creator A5052937372 @default.
• W3111257261 creator A5061648315 @default.
• W3111257261 creator A5066717752 @default.
• W3111257261 creator A5085205118 @default.
• W3111257261 date "2020-12-17" @default.
• W3111257261 modified "2023-10-17" @default.
• W3111257261 title "Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations" @default.
• W3111257261 cites W2111662961 @default.
• W3111257261 cites W2132157071 @default.
• W3111257261 cites W2133149289 @default.
• W3111257261 cites W2135192471 @default.
• W3111257261 cites W2135403187 @default.
• W3111257261 cites W2137005514 @default.
• W3111257261 cites W2149733252 @default.
• W3111257261 cites W2210071992 @default.
• W3111257261 cites W2339311613 @default.
• W3111257261 cites W2587420003 @default.
• W3111257261 cites W2760639821 @default.
• W3111257261 cites W2806325305 @default.
• W3111257261 cites W2921027277 @default.
• W3111257261 cites W2962479261 @default.
• W3111257261 cites W2975758168 @default.
• W3111257261 cites W2981797636 @default.
• W3111257261 cites W2990041408 @default.
• W3111257261 doi "https://doi.org/10.1007/s40265-020-01441-6" @default.
• W3111257261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7932969" @default.
• W3111257261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33331989" @default.
• W3111257261 hasPublicationYear "2020" @default.
• W3111257261 type Work @default.
• W3111257261 sameAs 3111257261 @default.
• W3111257261 citedByCount "45" @default.
• W3111257261 countsByYear W31112572612021 @default.
• W3111257261 countsByYear W31112572612022 @default.
• W3111257261 countsByYear W31112572612023 @default.
• W3111257261 crossrefType "journal-article" @default.
• W3111257261 hasAuthorship W3111257261A5003464447 @default.
• W3111257261 hasAuthorship W3111257261A5005962138 @default.
• W3111257261 hasAuthorship W3111257261A5011935052 @default.
• W3111257261 hasAuthorship W3111257261A5016050402 @default.
• W3111257261 hasAuthorship W3111257261A5024261346 @default.
• W3111257261 hasAuthorship W3111257261A5026909873 @default.
• W3111257261 hasAuthorship W3111257261A5028631107 @default.
• W3111257261 hasAuthorship W3111257261A5035532245 @default.
• W3111257261 hasAuthorship W3111257261A5038776794 @default.
• W3111257261 hasAuthorship W3111257261A5043607755 @default.
• W3111257261 hasAuthorship W3111257261A5044887899 @default.
• W3111257261 hasAuthorship W3111257261A5052159787 @default.
• W3111257261 hasAuthorship W3111257261A5052937372 @default.
• W3111257261 hasAuthorship W3111257261A5061648315 @default.
• W3111257261 hasAuthorship W3111257261A5066717752 @default.
• W3111257261 hasAuthorship W3111257261A5085205118 @default.
• W3111257261 hasBestOaLocation W31112572611 @default.
• W3111257261 hasConcept C121608353 @default.
• W3111257261 hasConcept C126322002 @default.
• W3111257261 hasConcept C143998085 @default.
• W3111257261 hasConcept C168563851 @default.
• W3111257261 hasConcept C204243189 @default.
• W3111257261 hasConcept C207103383 @default.
• W3111257261 hasConcept C2776256026 @default.
• W3111257261 hasConcept C2779438470 @default.
• W3111257261 hasConcept C2780580887 @default.
• W3111257261 hasConcept C44249647 @default.
• W3111257261 hasConcept C71924100 @default.
• W3111257261 hasConceptScore W3111257261C121608353 @default.
• W3111257261 hasConceptScore W3111257261C126322002 @default.
• W3111257261 hasConceptScore W3111257261C143998085 @default.
• W3111257261 hasConceptScore W3111257261C168563851 @default.
• W3111257261 hasConceptScore W3111257261C204243189 @default.
• W3111257261 hasConceptScore W3111257261C207103383 @default.
• W3111257261 hasConceptScore W3111257261C2776256026 @default.
• W3111257261 hasConceptScore W3111257261C2779438470 @default.
• W3111257261 hasConceptScore W3111257261C2780580887 @default.
• W3111257261 hasConceptScore W3111257261C44249647 @default.
• W3111257261 hasConceptScore W3111257261C71924100 @default.
• W3111257261 hasFunder F4320307765 @default.
• W3111257261 hasIssue "2" @default.
• W3111257261 hasLocation W31112572611 @default.
• W3111257261 hasLocation W31112572612 @default.
• W3111257261 hasLocation W31112572613 @default.
• W3111257261 hasLocation W31112572614 @default.
• W3111257261 hasOpenAccess W3111257261 @default.
• W3111257261 hasPrimaryLocation W31112572611 @default.
• W3111257261 hasRelatedWork W1988356095 @default.
• W3111257261 hasRelatedWork W1999967090 @default.

• next